Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

GPR153 Inhibitors

GPR153 inhibitors encompass a diverse array of chemical compounds that suppress the functional activity of GPR153 through modulation of various neuromodulatory signaling pathways. Haloperidol and SCH 23390, by antagonizing D2 and D1 dopamine receptors respectively, potentially limit dopaminergic crosstalk with GPR153 signaling, leading to decreased GPR153 activity. Similarly, the alpha-adrenergic antagonist phentolamine and beta-adrenergic antagonist propranolol may attenuate GPR153 function by modifying adrenergic pathways that possibly intersect with GPR153-mediated processes. Serotonin receptor antagonists such as ketanserin and Volinanserin, targeting 5-HT2A receptors, along with ondansetron, which targets 5-HT3 receptors, could reduce GPR153 activity by influencing serotonergic neurotransmission, a system that may interact with GPR153 signaling. Yohimbine's antagonistic effect on alpha-2 adrenergic receptors and rimonabant's action on CB1 cannabinoid receptors offer additional routes for the indirect suppression of GPR153 by modulating respective signaling pathways that could potentially regulate GPR153 activity. Furthermore, LY 341495 and MPEP, as antagonists of group II metabotropic glutamate receptors and the mGlu5 receptor respectively, may lower GPR153 activity by affecting glutamatergic signaling. The influence of glutamatergic neurotransmission on GPR153 activity is further supported by 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione, Disodium Salt, an AMPA receptor antagonist, which could impair excitatory synaptic signaling pathways that impact GPR153 function. Collectively, these inhibitors contribute to the downregulation of GPR153 activity by targeting specific neurotransmitter systems and their receptors, which are likely to engage in regulatory interactions with GPR153. Through these targeted actions, the selected compounds effectively diminish the functional activity of GPR153, demonstrating their potential to indirectly inhibit this protein by intervening in signaling pathways critical for its regulation.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Haloperidol

52-86-8sc-507512
5 g
$190.00
(0)

Haloperidol, a D2 dopamine receptor antagonist, indirectly diminishes GPR153 activity by modulating downstream dopaminergic signaling pathways, which could interfere with GPR153's role in neuromodulation.

SCH 23390

125941-87-9sc-200408
sc-200408A
5 mg
25 mg
$175.00
$719.00
2
(1)

SCH 23390 is a selective D1 dopamine receptor antagonist that may reduce GPR153 functional activity by altering the balance of dopamine signaling, potentially affecting pathways that GPR153 is associated with.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Propranolol, a beta-adrenergic receptor antagonist, may lead to the inhibition of GPR153 by attenuating the adrenergic pathways that could overlap with GPR153's regulatory functions in the central nervous system.

Ketanserin

74050-98-9sc-279249
1 g
$700.00
(0)

Ketanserin, a 5-HT2A serotonin receptor antagonist, can potentially diminish GPR153 activity by modulating serotonergic signaling, a pathway that could crosstalk with GPR153's neuromodulatory actions.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$80.00
$326.00
1
(0)

Ondansetron, a 5-HT3 receptor antagonist, may indirectly inhibit GPR153 activity through the modulation of serotonin pathways that could interact with GPR153 signaling in the central nervous system.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$50.00
$168.00
$520.00
2
(1)

Yohimbine, an alpha-2 adrenergic receptor antagonist, could lead to decreased GPR153 activity by influencing the adrenergic signaling pathways that may have a regulatory relationship with GPR153.

Rimonabant

168273-06-1sc-205491
sc-205491A
5 mg
10 mg
$72.00
$160.00
15
(1)

Rimonabant, a CB1 cannabinoid receptor antagonist, may indirectly decrease GPR153 activity by modulating endocannabinoid signaling, which could intersect with signaling pathways involving GPR153.

LY 341495

201943-63-7sc-361244
sc-361244A
1 mg
10 mg
$87.00
$219.00
1
(1)

LY 341495, a selective group II (mGlu2/3) metabotropic glutamate receptor antagonist, could diminish GPR153 activity by affecting glutamatergic signaling pathways potentially connected to GPR153.

MPEP hydrochloride

96206-92-7sc-279454A
sc-279454
10 mg
50 mg
$133.00
$510.00
(0)

MPEP, a potent and selective non-competitive mGlu5 receptor antagonist, may indirectly inhibit GPR153 by modulating glutamate signaling, which may crosstalk with GPR153's functional mechanisms.

6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione

118876-58-7sc-478080
5 mg
$70.00
1
(0)

6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione, a selective AMPA receptor antagonist, could lead to the inhibition of GPR153 by altering excitatory neurotransmission, which could impact signaling pathways associated with GPR153.